Posted by Michael Wonder on 29 Sep 2020
Heron Therapeutics receives European Commission authorisation for Zynrelef (HTX-011) for the treatment of post-operative pain
28 September 2020 - Heron Therapeutics today announced that the European Commission has granted a marketing authorisation for Zynrelef (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.
The marketing authorisation follows the EMA's positive opinion from the CHMP in July 2020. Heron currently expects to make Zynrelef available to patients in the European Union (EU) during 2021.
The European Commission's authorisation is based on the results of Heron's two multi-center, double-blind, active and placebo-controlled Phase 3 studies of Zynrelef.
